ARQT News & Events

Arcutis Biotherapeutics announced the promotion of Mas Matsuda, JD, currently senior vice president and general counsel, to executive vice president, chief legal officer, and corporate secretary. Matsuda will continue to lead the Company's legal, compliance, and governance strategy in support of the continued growth of the Company, commercialization of the ZORYVE portfolio, and protection of the Company's intellectual property, as well as any corporate transactions.

Arcutis Biotherapeutics, announced that the first participant has been enrolled in a Phase 1a/1b, double-blind, randomized, placebo-controlled study, ARQ-234-131, evaluating the safety and tolerability of ARQ-234. The investigational biologic, administered as a subcutaneous injection, is being evaluated in sequential cohorts, with single-ascending-dose cohorts in healthy volunteers and adults with moderate to severe atopic dermatitis, followed by multiple-ascending-dose cohorts and a small proof-of-concept cohort in the adults with atopic dermatitis.